TFR Capital LLC. Invests $2.49 Million in McKesson Corporation $MCK

Key Points

• TFR Capital purchased 3,290 McKesson shares worth approximately $2.49 million in the second quarter. Institutional investors collectively own 85.07% of the company.
• McKesson exceeded quarterly expectations, reporting $9.93 EPS and $105.38 billion in revenue, with revenue up 7.7% year over year. The company issued fiscal 2027 EPS guidance of $44.20–$45.00.
• McKesson raised its quarterly dividend to $0.94 per share, while analysts maintained a generally positive outlook with a “Moderate Buy” consensus and an average price target of $977.

TFR Capital LLC. purchased a new stake in McKesson Corporation (NYSE:MCK - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 3,290 shares of the company's stock, valued at approximately $2,486,000.

A number of other institutional investors have also made changes to their positions in the company. University of Texas Texas AM Investment Management Co. bought a new stake in McKesson during the fourth quarter valued at $25,000. Swiss RE Ltd. acquired a new stake in shares of McKesson during the fourth quarter worth $26,000. State of Wyoming bought a new position in shares of McKesson in the 2nd quarter worth about $29,000. Kingdom Financial Group LLC. bought a new position in shares of McKesson in the 4th quarter worth about $33,000. Finally, Birchwood Financial Partners Inc. acquired a new position in shares of McKesson in the 4th quarter valued at about $33,000. 85.07% of the stock is currently owned by institutional investors.

McKesson Trading Up 1.4%

MCK stock opened at $868.72 on Friday. McKesson Corporation has a 52 week low of $667.50 and a 52 week high of $999.00. The company has a market capitalization of $101.28 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 1.71 and a beta of 0.30. The firm's 50-day moving average is $813.45 and its two-hundred day moving average is $842.81.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The firm had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. During the same period last year, the company posted $8.26 EPS. The firm's quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, equities research analysts predict that McKesson Corporation will post 44.65 earnings per share for the current year.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Tuesday, September 1st. This is a boost from McKesson's previous quarterly dividend of $0.82. McKesson's dividend payout ratio is presently 8.78%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MCK. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $875.00 target price on shares of McKesson in a report on Friday, May 8th. UBS Group lifted their target price on McKesson from $1,050.00 to $1,080.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Citigroup upped their target price on McKesson from $945.00 to $1,000.00 and gave the company a "buy" rating in a report on Friday, July 24th. Finally, Weiss Ratings cut McKesson from a "buy (b)" rating to a "buy (b-)" rating in a research report on Tuesday, July 7th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, McKesson has an average rating of "Moderate Buy" and an average price target of $977.00.

Insider Activity

In other news, EVP Thomas L. Rodgers sold 699 shares of the business's stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total transaction of $513,953.73. Following the sale, the executive vice president owned 2,268 shares in the company, valued at $1,667,592.36. The trade was a 23.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the sale, the executive vice president directly owned 3,247 shares in the company, valued at approximately $2,471,259.23. This trade represents a 52.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 29,049 shares of company stock worth $22,530,626. 0.06% of the stock is owned by company insiders.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source